IDOR 11342831
Alternative Names: IDO-090; IDOR-1134-2831Latest Information Update: 02 Sep 2026
At a glance
- Originator Idorsia Pharmaceuticals
- Class Bacterial vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Clostridium difficile infections
Most Recent Events
- 30 Jul 2026 Idorsia Pharmaceuticals plans the US label‑enabling study confirming the benefits of QUVIVIQ on daytime functioning, in the coming weeks
- 30 Jul 2026 IDOR 11342831 is available for licensing as of 30 Jul 2026. https://www.idorsia.com/contact/business-development
- 01 Jun 2026 Immunogenicity and adverse evenet data from a phase I trial in Clostridium difficile infections released by Idorsia Pharmaceuticals